Skip to main content

Table 1 Patients’ and lesions’ characteristics (n = 105)

From: Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study

Age, median (range) 58 (36–85)
Primary tumor  
Lung 49 (46.6%)
Breast 23 (22%)
Kidney 11 (10.5%)
Melanoma 10 (9.5%)
Gastrointestinal 5 (4.8%)
Gynecological 5 (4.8%)
Head & neck 1 (0.9%)
Bladder 1 (0.9%)
Concomitant systemic therapy  
Chemotherapy 29 (26.2%)
Targeted therapy 28 (25%)
Immunotherapy 15 (13.5%)
Hormone therapy 3 (2.8%)
None 29 (26.2%)
Unknown 7 (6.3%)
Previous WBRT  
Yes 15 (14%)
No 90 (86%)
Brainstem site (n = 111)  
Midbrain 33 (30%)
Pons 63 (57%)
Medulla oblongata 15 (13%)
Fraction number (n = 111)  
1 58 (52.3%)
2 1 (0.9%)
3 38 (34%)
4 2 (1.8%)
5 12 (11%)
Median total dose SRS (Gy) (range) 18 (12–20)
Median total dose HSRT (Gy) (range) 20 (14–32)
Median BED (Gy10) (range) 35.7 (23.8–60)
Median/mean GTV volume SRS (cc) (n = 58) 0.4/1.3 (0.02–2.8)
Median/mean GTV volume HSRT (cc) (n = 53) 0.4/1.5 (0.08–23.6)
  1. WBRT: whole-brain radiotherapy; SRS: stereotactic radiosurgery; HSRT: hypofractionated stereotactic radiotherapy, GTV: gross tumor volume